![](/img/cover-not-exists.png)
LBA-09 * Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
Ciardiello, F., Normanno, N., Martinelli, E., Troiani, T., Cardone, C., Nappi, A., Rachiglio, A. M., Lambiase, M., Pisconti, S., Giuliani, F., Barone, C., Biglietto, M., Montesarchio, V., Tonini, G.,Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv262.09
Date:
June, 2015
File:
PDF, 40 KB
english, 2015